glp-1 agonist depression Glucagon-like peptide-1 medicines in neurological and psychiatric disorders Most GLP-1 Medications Correlated with

Strategies to facilitate medication adherence, persistence and treatment intensification in people with T2D should be made a priority in order to achieve and maintain glycaemic targets and improve outcomes in this population

The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer

(WROC) Excellus BlueCross BlueShield is pushing back against reports that it will no longer cover GLP-1 medications, saying drugs used to treat certain medical conditions remain cove...

Next up: glucagon-like peptide 1 receptor agonists, known colloquially (and identified here) as GLPs

At the same time, ultra-long-acting injectables are emerging as another theme of innovation